What are Addyi (flibanserin) and Vyleesi (bremelanotide) now?
Addyi (flibanserin) and Vyleesi (bremelanotide) are two different oral/CGP-compliant treatments aimed at low sexual desire in premenopausal women, but they work differently and have different current prescribing patterns and restrictions.
- Addyi (flibanserin) is a daily oral medication used for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
- Vyleesi (bremelanotide) is an as-needed injectable medication for premenopausal women with HSDD that is not due to a medical or psychiatric condition or problems within the relationship.
Their “current status” mainly affects how clinicians choose between them (daily vs on-demand), and—importantly—how strictly they manage safety risks (especially alcohol and blood pressure/heart-rate considerations).
Key safety differences patients ask about
The biggest day-to-day practical difference is risk management.
Addyi (flibanserin)
- Has a known interaction with alcohol that can cause potentially serious sedation and low blood pressure.
- Because of that, patients are generally advised to avoid alcohol and follow specific timing/usage rules when taking the medication.
Vyleesi (bremelanotide)
- Can increase blood pressure and heart rate, and commonly causes nausea.
- It also has usage guidance tied to how often patients can take it, and it carries precautions around cardiovascular effects.
These differences often drive the choice between an ongoing daily option (Addyi) and an on-demand option (Vyleesi).
How does dosing/usage differ day-to-day?
Addyi
- Taken once daily (a “use it regularly” approach).
Vyleesi
- Used as an injection before anticipated sexual activity (a “take it when needed” approach), with limits on repeat dosing in a 24-hour period and in a month.
Because of this, “current status” in real-world use often maps to patient preference: some want a daily steady regimen, while others prefer only when anticipating sex.
Effect timing: when would patients expect results?
With Addyi, improvement is typically assessed over weeks because it’s a daily medication.
With Vyleesi, improvement is assessed around treatment cycles that include pre-planned use before sexual activity, reflecting its on-demand nature.
Patients commonly ask this because they need to know whether to continue a regimen if they do not see early changes.
Cost, insurance coverage, and access
Current access tends to depend heavily on payer coverage and prior authorization, which can differ by drug because of how they’re categorized, dosing patterns, and the specific label/risk requirements. If you’re comparing “current status” for buying or coverage, the most actionable step is checking the specific insurer’s formulary and whether they require prior authorization or documentation of eligibility (premenopausal HSDD diagnosis, exclusion of other causes, etc.).
Are they still on the market? Any major replacement by newer drugs?
Both drugs remain established options for HSDD in premenopausal women, but the “current status” from a patient perspective usually means:
- whether the drug is accessible through local formularies,
- whether prescribers feel comfortable managing the labeled risk profile,
- and how often patients can tolerate the main side effects (sedation/low blood pressure concerns for Addyi; nausea and possible blood pressure/heart rate effects for Vyleesi).
What to ask your clinician before choosing between them
A practical decision often comes down to:
- alcohol use patterns (Addyi is the bigger concern here),
- history of hypertension, cardiac disease, or uncontrolled cardiovascular risk (Vyleesi is the bigger concern here),
- tolerability of nausea (Vyleesi),
- willingness to take a daily medication (Addyi) versus as-needed injection (Vyleesi),
- and how long you’re willing to trial the therapy before judging effectiveness.
If you want, tell me your country (and whether you’re looking for “US FDA status” specifically), and whether this is for a personal comparison or for formulary/reimbursement research. I can tailor the “current status” to the regulatory environment and typical coverage pathways.